Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 173

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 173
---
 that our team is well positioned to execute on our strategy to develop and, if approved, commercialize these three ADCs and future pipeline assets to ultimately bring broad benefit to cancer patients worldwide. Our Strategy Our vision is to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treatcancers. The principal components of our strategy include:

| • |     | We leverage “next wave” ADC architecture. Recently, next wave ADCs have been associated                                                                                                                                                    
 with double-digit improvement in objective response rates (“ORR”) over first generation ADCs against the same target across a variety of solid tumors, including ovarian, breast cancer, and lung cancers. Next wave ADC architectures are 
 typified by improved linker-antibody stability, optimized                                                                                                                                                                                  |

- 116 -

| pharmacokinetics and improved inhibitor payloads, such as using TOPO1 in lieu of monomethyl auristatin E (“MMAE”). |

| • |     | We preferentially pursue clinically validated targets and identify opportunities for                                                                                                                                                               
 differentiation. Rather than expend resources on target discovery, we leverage our team’s deep experience in oncology and biologics, review existing oncology target literature and engage with key opinion leaders to identify promising          
 tumor antibodies, antibody conjugates, and antigens. We focus on tumor targets of product candidates previously tested in clinical trials by other biopharmaceutical companies and where the trials results were made available, the rationale for 
 discontinuation of such product candidates were well-known and where we have identified opportunities for differentiation. We also prioritize those targets that we believe have both strong precedent data and potential broader applicability,   
 including expansion beyond the indications in which they were initially tested.                                                                                                                                                                    |

| • |     | We innovate antibody design to improve ADC performance. We strive to develop ADCs that couple next                                                                                                            
 wave ADC architecture with cutting-edge antibody strategies to further improve antibody performance, including, but not limited to, high affinity, biparatopic/bi-specific, epitope and Fc modifications that 
 increase ADC potency or safety.                                                                                                                                                                               |

| • |     | We focus our development strategies to demonstrate differentiation of our assets compared to first                                                                                                                                                                                                                                                                                                                                    
 generation ADCs to maximize our asset’s competitive profile. Our development strategy leverages precedent data from first generation ADCs to benchmark potential improvements to guide further expansion in both precedent and non-precedent indications. We also plan to pursue combination strategies early in our programs to reach more patients and take full advantage of Project Fron